Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-011031
Filing Date
2025-05-15
Accepted
2025-05-15 16:45:34
Documents
81
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 740627
2 ex31-1.htm EX-31.1 8955
3 ex31-2.htm EX-31.2 8783
4 ex32-1.htm EX-32.1 5617
5 ex32-2.htm EX-32.2 5622
  Complete submission text file 0001641172-25-011031.txt   4926525

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bfri-20250331.xsd EX-101.SCH 44479
7 XBRL CALCULATION FILE bfri-20250331_cal.xml EX-101.CAL 72931
8 XBRL DEFINITION FILE bfri-20250331_def.xml EX-101.DEF 218935
9 XBRL LABEL FILE bfri-20250331_lab.xml EX-101.LAB 352733
10 XBRL PRESENTATION FILE bfri-20250331_pre.xml EX-101.PRE 299134
83 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 548477
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40943 | Film No.: 25954612
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)